Do Women With Breast Cancer Who Choose Adjunctive Integrative Oncology Care Receive Different Standard Oncologic Treatment?
Leanna J Standish, Fred Dowd, Erin Sweet, Linda Dale, M Robyn Andersen, Leanna J Standish, Fred Dowd, Erin Sweet, Linda Dale, M Robyn Andersen
Abstract
Purpose: To determine if women with breast cancer who choose adjunctive naturopathic oncology (NO) specialty care receive different standard oncologic treatment when compared with breast cancer patients who receive only standard care.
Participants: Women with breast cancer stages 0 to 4, aged 18+ who spoke English and sought care from outpatient naturopathic doctor clinics were enrolled in an observational study of clinical and quality of life outcomes. Women who sought NO care 2 or more times within the first 2 years postdiagnosis were identified as NO cases. A matched comparison group of breast cancer patients were identified using the Western Washington Cancer Surveillance System(CSS).
Methods: A longitudinal cohort design. In addition to self-report data, the CSS provided data on demographics, stage at the time of diagnosis, and initial treatment. Oncology medical records were abstracted in order to provide additional information on standard oncologic treatment for all participants.
Results: Cohorts were well matched with regard to demographic, histologic, and prognostic indicators at the time of diagnosis. Approximately 70% of women in both cohorts received standard oncologic care that met the National Comprehensive Cancer Network guidelines. There were no statistically significant differences between the cohorts in treatment received. Fewer women in the NO cohort with estrogen receptor-positive breast cancer appear to have received antiestrogen therapy.
Conclusions: Women in both cohorts appear to receive guideline-concordant care. However, women who receive adjunctive NO care may be less likely to receive antiestrogen therapy.
Trial registration: ClinicalTrials.gov NCT01366248.
Keywords: breast cancer; complementary and alternative medicine; integrative oncology; observational study.
Conflict of interest statement
Declaration of Conflicting Interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
References
- Hack CC, Voisß P, Lange S, et al. Local and systemic therapies for breast cancer patients: reducing short-term symptoms with the methods of integrative medicine. Geburtshilfe Frauenheilkd. 2015;75:675-682.
- Friedenreich C, Lynch B. Can living a less sedentary life decrease breast cancer risk in women? Womens Health (Lond). 2012;8:5-7.
- Rao MR, Raghuram N, Nagendra HR, et al. Anxiolytic effects of a yoga program in early breast cancer patients undergoing conventional treatment: a randomized controlled trial. Complement Ther Med. 2009;17:1-8.
- Adler SR, Wrubel J, Hughes E, Beinfield H. Patients’ interactions with physicians and complementary and alternative medicine practitioners: older women with breast cancer and self-managed health care. Integr Cancer Ther. 2009;8:63-70.
- Ballard-Barbash R, Friedenreich CM, Courneya KS, Siddiqi SM, McTiernan A, Alfano CM. Physical activity, biomarkers, and disease outcomes in cancer survivors: a systematic review. J Natl Cancer Inst. 2012;104:815-840.
- Saquib J, Parker BA, Natarajan L, et al. Prognosis following the use of complementary and alternative medicine in women diagnosed with breast cancer. Complement Ther Med. 2012;20:283-290.
- Chang EY, Glissmeyer M, Tonnes S, Hudson T, Johnson N. Outcomes of breast cancer in patients who use alternative therapies as primary treatment. Am J Surg. 2006;192:471-473.
- Andersen MR, Tyree PT, Devlin SM, Diehr PK, Lafferty WE. Do insured women who use CAM providers also receive recommended mammography? J Soc Integr Oncol. 2010;8:114.
- Andersen MR, Osborn B, Sweet E, Dowd F, Standish L. Integrative oncology consultation does not delay initiation of primary treatment for breast cancer. Ann Behav Med. 2013;45(suppl):S178.
- Standish LJ, Sweet E, Naydis E, Andersen MR. Can we demonstrate that breast cancer “integrative oncology” is effective? A methodology to evaluate the effectiveness of integrative oncology offered in community clinics. Integr Cancer Ther. 2013;12:126-135.
- Standish LJ, Dowd F, Sweet E, et al. Breast cancer integrative oncology care and its costs. Integr Cancer Ther. 2017;16:85-95.
- Hassett MJ, Hughes ME, Niland JC, et al. Selecting high priority quality measures for breast cancer quality improvement. Med Care. 2008;46:762-770.
- Lafferty WE, Bellas A, Baden AC, Tyree PT, Standish LJ, Patterson R. The use of complementary and alternative medical providers by insured cancer patients in Washington State. Cancer. 2004;100:1522-1530.
- Lafferty WE, Tyree PT, Devlin SM, Andersen MR, Diehr PK. Complementary and alternative medicine provider use and expenditures by cancer treatment phase. Am J Manag Care. 2008;14:326-334.
Source: PubMed